I am Dr. Gabriela Rozic, a Principal Investigator at the Institute for Personalized and Translational Medicine at Ariel University, specializing in precision oncology and cancer therapeutics. My research integrates advanced 3D tumor models, such as "assembloids," with genomics and transcriptomics data to optimize personalized drug selection in cancer therapy. I focus on developing innovative cancer treatments, particularly targeting microtubules and tumor-stromal interactions, with an emphasis on patient-specific models to enhance therapeutic outcomes.
I have made significant contributions to research on multiple myeloma and gastric cancer, with a strong expertise in data analysis, particularly RNA sequencing and whole exome sequencing. Over the years, I have authored numerous patents and publications in cancer biology and drug development.
In addition to my research, I teach advanced molecular biology techniques at Ariel University. With a background in neurobiology and molecular cancer biology, I bring a multidisciplinary approach to addressing complex challenges in cancer treatment.
I am Dr. Gabriela Rozic, a Principal Investigator at the Institute for Personalized and Translational Medicine at Ariel University, specializing in precision oncology and cancer therapeutics. My research integrates advanced 3D tumor models, such as "assembloids," with genomics and transcriptomics data to optimize personalized drug selection in cancer therapy. I focus on developing innovative cancer treatments, particularly targeting microtubules and tumor-stromal interactions, with an emphasis on patient-specific models to enhance therapeutic outcomes.
I have made significant contributions to research on multiple myeloma and gastric cancer, with a strong expertise in data analysis, particularly RNA sequencing and whole exome sequencing. Over the years, I have authored numerous patents and publications in cancer biology and drug development.
In addition to my research, I teach advanced molecular biology techniques at Ariel University. With a background in neurobiology and molecular cancer biology, I bring a multidisciplinary approach to addressing complex challenges in cancer treatment.